Intellego Technologies AB

INT

SE0016075063

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 11:29:37 2024-05-31 am EDT			5-day change	1st Jan Change
29 ^SEK	-.--%		-5.84%	+71.60%

Apr. 30	Sweden's Intellego Technologies Names CFO	MT
Apr. 30	Intellego Technologies AB Appoints Petra Olofsson as Chief Financial Officer	CI

Intellego Technologies AB has completed an IPO in the amount of SEK 14.999998 million.

June 24, 2021 at 12:00 am EDT

Intellego Technologies AB has completed an IPO in the amount of SEK 14.999998 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 2,083,333 PriceRange: SEK 7.2

Latest news about Intellego Technologies AB

Sweden's Intellego Technologies Names CFO	Apr. 30	MT
Intellego Technologies AB Appoints Petra Olofsson as Chief Financial Officer	Apr. 30	CI
Intellego Technologies AB Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 30	CI
Intellego Technologies AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 21	CI
Intellego Technologies Obtains Up to SEK40 Million Credit Line Ahead of New Product Launches	Feb. 06	MT
Intellego Technologies AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-25	CI
Intellego Technologies AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
Intellego Technologies AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-06-07	CI
Intellego Technologies AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-03-02	CI
Certain Shares of Intellego Technologies AB are subject to a Lock-Up Agreement Ending on 24-DEC-2022.	22-12-23	CI
Intellego Technologies AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-24	CI
Intellego Technologies AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-25	CI
Intellego Technologies AB (OM:INT) agreed to acquire Daro Group Limited for Ãº10 million.	22-08-22	CI
Intellego Technologies AB Reports Earnings Results for the First Quarter Ended March 31, 2022	22-06-08	CI
Intellego Technologies AB (OM:INT) signed letter of intent to acquire majority stake in Jiangyin Feiyang Instrument Co., Ltd	22-05-19	CI
Intellego Technologies AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	22-02-24	CI
Intellego Technologies AB Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-24	CI
Certain Shares of Intellego Technologies AB are subject to a Lock-Up Agreement Ending on 24-DEC-2021.	21-12-23	CI
Intellego Technologies AB has completed an IPO in the amount of SEK 14.999998 million.	21-06-24	CI
Intellego Technologies AB has filed an IPO in the amount of SEK 14.999998 million.	21-05-27	CI

Chart Intellego Technologies AB

Duration

Period

More charts

Intellego Technologies AB is a Sweden-based company engaged in photochromatic indicator technology. The Company is a manufacturer of colorimetric ultraviolet indicators. UVC Dosimeters are used in Healthcare, Hospitality, Retail, Transportation and Commercial Applications around the world. With its patented photochromic ink that changes color based on exposure to ultraviolet irradiation or specific substances, Intellego produces dosimeters in a variety of formats and custom options to meet the constantly evolving needs of Ultraviolet Device Manufacturers (OEMs) and end-users. Intellego Technologies is headquartered in Stockholm, with product development and manufacturing based in the southwest region of Sweden.

Sector

Biotechnology & Medical Research

Calendar

2024-08-25 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
INTELLEGO TECHNOLOGIES AB	+71.60%	72.55M
MODERNA, INC.	+43.36%	54.64B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.52%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B